Gilead Sciences, Inc. (FRA:GIS)
96.13
+0.93 (0.98%)
At close: Sep 29, 2025
Gilead Sciences Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
€1,396,412
Profits / Employee
€305,330
Market Cap
119.11B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 17,600 | -400 | -2.22% |
Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
Dec 31, 2021 | 14,400 | 800 | 5.88% |
Dec 31, 2020 | 13,600 | 1,800 | 15.25% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Siemens Energy AG | 98,000 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Deutsche Bank Aktiengesellschaft | 89,753 |
Gilead Sciences News
- 12 days ago - May 2026 Options Now Available For Gilead Sciences (GILD) - Nasdaq
- 13 days ago - Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management - Wallstreet:Online
- 13 days ago - Fangzhou Wins Gilead ‘Award of Excellence' for AI-Driven Chronic Disease Management - GlobeNewsWire
- 13 days ago - GILD Partners with Nurix for Potential IRAK4 Protein Degrader - GuruFocus
- 14 days ago - Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus
- 14 days ago - QQQM, GOOGL, ADBE, GILD: Large Inflows Detected at ETF - Nasdaq
- 14 days ago - GILD: JP Morgan Raises Price Target, Reaffirms Overweight Rating | GILD Stock News - GuruFocus
- 15 days ago - Validea Detailed Fundamental Analysis - GILD - Nasdaq